Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
November 25th, 2008
Genomic Health, Inc. (NASDAQ:GHDX) announced the publication of results from a study indicating that Oncotype DX(R) Recurrence Score(R) results impact the way physicians treat early-stage breast cancer. The study, published in the October issue of the American Journal of Surgery, showed that treatment changed as a result of Oncotype DX in 44 percent of patients with node- negative estrogen receptor-positive breast cancer. "The results of this study confirm that the decision to administer chemotherapy in node-negative estrogen receptor-positive breast cancer patients should no longer be based solely on traditional clinical and pathologic criteria, but also by integrating...
Source: Cancer Weekly (2008-11-25)
|
